Partial agonist activity of celiprolol, a cardioselective β-antagonist

[1]  H. Jin,et al.  Partial agonist activity of celiprolol as assessed in conscious unrestrained dogs in comparison with those of pindolol and labetalol. , 1989, Arzneimittel-Forschung.

[2]  W. Frishman,et al.  Beta-adrenergic receptor blockers. Adverse effects and drug interactions. , 1988, Hypertension.

[3]  A. Hjalmarson.  Do Results from Major Clinical Trials Indicate a Change in Management in the Acute Phase of Myocardial Infarction? , 1987, Journal of cardiovascular pharmacology.

[4]  D. McDevitt.  Pharmacological characteristics of beta blockers and their role in clinical practice. , 1986, Journal of cardiovascular pharmacology.

[5]  H. Sokabe.  A new classification of -adrenoceptor blocking drugs , 1985 .

[6]  S. Imai,et al.  Alpha-blockade and vasodilatation induced by nipradilol, arotinolol and labetalol in pithed rats. , 1985, Japanese journal of pharmacology.

[7]  S. Imai,et al.  Pharmacological profile of a new beta-adrenoceptor blocker, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696). , 1984, Arzneimittel-Forschung.

[8]  義人 仲川,et al.  Labetalolのαおよびβ遮断作用と冠循環，心機能，心筋エネルギー代謝に対する作用について , 1978 .

[9]  T. Kawada,et al.  Comparison of beta-adrenergic blocking activities of propranolol, isopropylmethoxamine, sotalol, practolol, alprenolol, pindolol, oxprenolol and D-32 in the atria and trachea of the guinea-pig. , 1974, Arzneimittel-Forschung.